Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XRD 0394

Next Previous
Drug Profile

XRD 0394

Alternative Names: XRD-0394

Latest Information Update: 24 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XRad Therapeutics
  • Class Antineoplastics; Radioprotectives; Small molecules
  • Mechanism of Action Ataxia telangiectasia mutated protein inhibitors; DNA-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 24 Feb 2025 Phase-I development is ongoing in USA (NCT05002140)
  • 20 Feb 2025 XRad Therapeutics and NYU Langone Health plan a phase 0 (an early phase I) trial for Glioma (Combination therapy, Recurrent, Late-stage disease, First-line therapy) in USA (PO), in April 2025 (NCT06829173)
  • 05 Apr 2024 Adverse events and pharmacokinetic data from a phase I trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top